| Combined amphiregulin and epiregulin expression as a prognostic and predictive biomarker of panitumumab (Pmab), fluorouracil, and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212). |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3528 |
|
|
| t. Dermatology-related quality of life outcomes in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: A prespecified secondary analysis of the phase 2 randomized PanaMa (AIO KRK 0212) trial |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e15539 |
|
|
| FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses. |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3506 |
|
|
| Spatial patterns in the tumor immune microenvironment as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype (wt) metastatic colorectal cancer (mCRC): PanaMa (AIO KRK0212) trial |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2024.42.16_suppl.3539 |
|
|
| Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa. |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1200/JCO.2024.42.16_suppl.3529 |
|
|
| Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer. |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1200/JCO.2024.42.16_suppl.e14625 |
|
|
| Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials. |
|
|
| Ann Oncol 35 (Supplement 2, 58P): 235 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1016/j.annonc.2024.08.067 |
|
|
| Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315) |
|
|
| J Clin Oncol 42(26): 3094-104 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1200/JCO.23.01566 |
|
|
| Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. |
|
|
| Lancet G&H 9: 734-44 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1016/ S2468-1253(24)00119-5 |
|
|
| Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315). |
|
|
| J Clin Oncol |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| ascopubs.org/doi/full/10.1200/JCO.23.01566 |
|
|
